Cell line name |
HUMEMS |
Accession |
CVCL_S872 |
Resource Identification Initiative |
To cite this cell line use: HUMEMS (RRID:CVCL_S872) |
Comments |
Population: Japanese. Misspelling: HUMENS; PubMed=20712710. Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175. |
Sequence variations |
- Gene fusion; HGNC; 3819; FOXO1 + HGNC; 8617; PAX3; Name(s)=PAX3-FOXO1, PAX3-FKHR (PubMed=17547718).
|
Disease |
Alveolar rhabdomyosarcoma (NCIt: C3749) Alveolar rhabdomyosarcoma (ORDO: Orphanet_99756) |
Species of origin |
Homo sapiens (Human)
(NCBI Taxonomy: 9606) |
Sex of cell |
Female |
Age at sampling |
13Y |
Category |
Cancer cell line |
Publications | PubMed=17547718; DOI=10.1111/j.1749-0774.2007.00029.x Ohi S. Characterization, anticancer drug susceptibility and atRA-induced growth inhibition of a novel cell line (HUMEMS) established from pleural effusion of alveolar rhabdomyosarcoma of breast tissue. Hum. Cell 20:39-51(2007) PubMed=20712710; DOI=10.1111/j.1749-0774.2010.00086.x Suzuki M., Tominaga N., Ide Y., Ohyama A., Nakahara T., Ishikawa H., Tanaka A., Mataga I. Establishment and characterization of the rhabdomyosarcoma cell line designated NUTOS derived from the human tongue sarcoma: special reference to the susceptibility of anti-cancer drugs. Hum. Cell 23:65-73(2010) PubMed=23882450; DOI=10.3389/fonc.2013.00183 Hinson A.R.P., Jones R., Crose L.E.S., Belyea B.C., Barr F.G., Linardic C.M. Human rhabdomyosarcoma cell lines for rhabdomyosarcoma research: utility and pitfalls. Front. Oncol. 3:183.1-183.12(2013) PubMed=23665679; DOI=10.1038/onc.2013.129 Sokolowski E., Turina C.B., Kikuchi K., Langenau D.M., Keller C. Proof-of-concept rare cancers in drug development: the case for rhabdomyosarcoma. Oncogene 33:1877-1889(2014) |
Cross-references |
Encyclopedic resources |
Wikidata; Q54896877
|
Entry history |
Entry creation | 03-Feb-2014 |
Last entry update | 29-Jun-2023 |
Version number | 14 |
---|